Do analysts recommend RDY or DYN?

Dyne Therapeutics has a consensus price target of $33.85, indicating a potential upside of 70.94%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 2.93

Does the media prefer RDY or DYN?

In the previous week, Dyne Therapeutics had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 14 mentions for Dyne Therapeutics and 1 mentions for Dr. Reddy's Laboratories. Dyne Therapeutics' average media sentiment score of 0.89 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARWR or DYN?

In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 14 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 1.43 beat Dyne Therapeutics' score of 0.89 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 10 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RGC or DYN?

Dyne Therapeutics has a consensus price target of $33.85, suggesting a potential upside of 70.94%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyne Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 2.93

Which has preferable earnings & valuation, RGC or DYN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is RGC or DYN more profitable?

Regencell Bioscience's return on equity of 0.00% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Dyne Therapeutics N/A -58.28% -46.77%

Does the media prefer RGC or DYN?

In the previous week, Regencell Bioscience had 9 more articles in the media than Dyne Therapeutics. MarketBeat recorded 23 mentions for Regencell Bioscience and 14 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.89 beat Regencell Bioscience's score of 0.05 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 22 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CYTK or DYN?

In the previous week, Cytokinetics had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 16 mentions for Cytokinetics and 14 mentions for Dyne Therapeutics. Cytokinetics' average media sentiment score of 1.02 beat Dyne Therapeutics' score of 0.89 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or DYN?

In the previous week, Dyne Therapeutics had 6 more articles in the media than Krystal Biotech. MarketBeat recorded 14 mentions for Dyne Therapeutics and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.47 beat Dyne Therapeutics' score of 0.89 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Dyne Therapeutics (DYN) Competitors

$19.80 +0.60 (+3.13%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$19.98 +0.18 (+0.93%)

As of 06/18/2026 07:46 PM Eastern

Compare

DYN vs. RDY, ARWR, RGC, CYTK, and KRYS

Should you buy Dyne Therapeutics stock or one of its competitors? MarketBeat compares Dyne Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyne Therapeutics include Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Regencell Bioscience (RGC), Cytokinetics (CYTK), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Dr. Reddy's Laboratories has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.11	$456M	$0.58	22.96
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 13 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 14 mentions for Dyne Therapeutics and 1 mentions for Dr. Reddy's Laboratories. Dyne Therapeutics' average media sentiment score of 0.89 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Dyne Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Dyne Therapeutics has a consensus price target of $33.85, indicating a potential upside of 70.94%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

Summary

Dyne Therapeutics beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus price target of $86.36, suggesting a potential upside of 5.55%. Dyne Therapeutics has a consensus price target of $33.85, suggesting a potential upside of 70.94%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 14 articles in the media. Arrowhead Pharmaceuticals' average media sentiment score of 1.43 beat Dyne Therapeutics' score of 0.89 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	10 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Arrowhead Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	13.89	-$1.63M	-$2.15	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Summary

Dyne Therapeutics beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

In the previous week, Regencell Bioscience had 9 more articles in the media than Dyne Therapeutics. MarketBeat recorded 23 mentions for Regencell Bioscience and 14 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 0.89 beat Regencell Bioscience's score of 0.05 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	22 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Regencell Bioscience's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Dyne Therapeutics	N/A	-58.28%	-46.77%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Dyne Therapeutics has a consensus price target of $33.85, suggesting a potential upside of 70.94%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

Regencell Bioscience has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Summary

Dyne Therapeutics beats Regencell Bioscience on 7 of the 12 factors compared between the two stocks.

How does Dyne Therapeutics compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Dyne Therapeutics (NASDAQ:DYN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

96.7% of Dyne Therapeutics shares are held by institutional investors. 2.6% of Cytokinetics shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Dyne Therapeutics has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	111.34	-$784.96M	-$6.84	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

In the previous week, Cytokinetics had 2 more articles in the media than Dyne Therapeutics. MarketBeat recorded 16 mentions for Cytokinetics and 14 mentions for Dyne Therapeutics. Cytokinetics' average media sentiment score of 1.02 beat Dyne Therapeutics' score of 0.89 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyne Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Cytokinetics currently has a consensus price target of $99.30, indicating a potential upside of 26.05%. Dyne Therapeutics has a consensus price target of $33.85, indicating a potential upside of 70.94%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

Summary

Dyne Therapeutics beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

In the previous week, Dyne Therapeutics had 6 more articles in the media than Krystal Biotech. MarketBeat recorded 14 mentions for Dyne Therapeutics and 8 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.47 beat Dyne Therapeutics' score of 0.89 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	26.37	$204.83M	$7.48	46.53
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Krystal Biotech has a net margin of 53.92% compared to Dyne Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Krystal Biotech presently has a consensus price target of $340.56, indicating a potential downside of 2.16%. Dyne Therapeutics has a consensus price target of $33.85, indicating a potential upside of 70.94%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Krystal Biotech beats Dyne Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.17B	$2.99B	$6.66B	$12.38B
Dividend Yield	N/A	1.78%	2.68%	5.68%
P/E Ratio	-6.15	18.67	24.46	24.42
Price / Sales	N/A	682.46	577.04	128.85
Price / Cash	N/A	56.55	44.20	55.24
Price / Book	2.91	4.04	10.70	6.58
Net Income	-$446.21M	$75.79M	$3.57B	$337.29M
7 Day Performance	8.85%	0.39%	0.69%	0.60%
1 Month Performance	24.37%	2.65%	3.93%	5.00%
1 Year Performance	83.67%	24.70%	28.51%	31.05%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	3.0128 of 5 stars	$19.80 +3.1%	$33.85 +70.9%	+83.7%	$3.17B	N/A	N/A	100	Gap Up High Trading Volume
RDY Dr. Reddy's Laboratories	1.3773 of 5 stars	$13.23 -0.1%	N/A	-12.3%	$11.05B	$335.93B	22.80	27,527
ARWR Arrowhead Pharmaceuticals	1.9278 of 5 stars	$73.86 +1.1%	$87.80 +18.9%	+423.8%	$10.30B	$829.45M	N/A	400	Positive News Analyst Forecast
RGC Regencell Bioscience	0.3929 of 5 stars	$21.39 +7.0%	N/A	-81.0%	$9.88B	N/A	N/A	10
CYTK Cytokinetics	3.7082 of 5 stars	$67.90 -5.0%	$99.30 +46.2%	+140.7%	$8.89B	$88.04M	N/A	250	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. RDY, ARWR, RGC, CYTK, and KRYS

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Dyne Therapeutics compare to Regencell Bioscience?

Summary

How does Dyne Therapeutics compare to Cytokinetics?

Summary

How does Dyne Therapeutics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. RDY, ARWR, RGC, CYTK, and KRYS

How does Dyne Therapeutics compare to Dr. Reddy's Laboratories?

Which has stronger earnings & valuation, RDY or DYN?

Do institutionals & insiders have more ownership in RDY or DYN?

Which has more risk & volatility, RDY or DYN?

Does the media prefer RDY or DYN?

Is RDY or DYN more profitable?

Do analysts recommend RDY or DYN?

Summary

How does Dyne Therapeutics compare to Arrowhead Pharmaceuticals?

Which has more risk and volatility, ARWR or DYN?

Do analysts recommend ARWR or DYN?

Do institutionals and insiders hold more shares of ARWR or DYN?

Does the media favor ARWR or DYN?

Is ARWR or DYN more profitable?

Which has higher earnings & valuation, ARWR or DYN?

Summary

How does Dyne Therapeutics compare to Regencell Bioscience?

Does the media prefer RGC or DYN?

Do insiders & institutionals hold more shares of RGC or DYN?

Is RGC or DYN more profitable?

Which has preferable earnings & valuation, RGC or DYN?

Do analysts rate RGC or DYN?

Which has more volatility and risk, RGC or DYN?

Summary

How does Dyne Therapeutics compare to Cytokinetics?

Do institutionals & insiders have more ownership in CYTK or DYN?

Which has more volatility & risk, CYTK or DYN?

Which has better valuation and earnings, CYTK or DYN?

Does the media favor CYTK or DYN?

Is CYTK or DYN more profitable?

Do analysts rate CYTK or DYN?

Summary

How does Dyne Therapeutics compare to Krystal Biotech?

Does the media prefer KRYS or DYN?

Which has more volatility & risk, KRYS or DYN?

Which has better valuation & earnings, KRYS or DYN?

Is KRYS or DYN more profitable?

Do analysts recommend KRYS or DYN?

Do insiders and institutionals believe in KRYS or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools